Lipella pharmaceuticals announces fda clearance of ind for lp-310 for oral lichen planus

Lp-310 is an oral formulation of lipella's lead asset lp-10. pittsburgh , oct. 20, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: "lipo") ("lipella," "our, "us" or the "company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the u.s. food and drug administration (fda) has approved an investigational new drug (ind) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of lp-310 in patients with symptomatic oral lichen planus (olp), a highly morbid condition with no effective treatment.
LIPO Ratings Summary
LIPO Quant Ranking